Condition
Bile Duct Neoplasm
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
3 treatments under study, led by Parallel Stent
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 1/2 (1)
Phase 3 (1)
Trial Status
Recruiting1
Withdrawn1
Clinical Trials (2)
Research Network
Common Treatments
- Parallel Stent1
- Tivozanib1
- Ystent Bonastent Mhilar1
Active Sponsors
- Samsung Medical Center1
- National Cancer Institute (NCI)1
Top Investigators
Division of Gastroenterology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
National Cancer Institute (NCI)
Related Conditions
- Obstructive Jaundice1
- Biliary Tract Malignancy1
- Cholangiocarcinoma1